Compound Cloud has been identified in a recent Journal of Medicinal Chemistry publication as a key, cost-effective source for obtaining high-quality screening compound sets for drug discovery groups with limited resources.
BioAscent’s Compound Cloud is a unique, on-demand service providing rapid and cost-effective access to custom or pre-selected compound libraries in flexible and ready for screening plate formats.
With around 125,000 lead-like and drug-like compounds to select from, our service is both exceptionally customisable and rapidly accessible thereby helping discovery projects.
Our unique cherry-picking capabilities allow customers to select only the compounds they are interested in, significantly lowering the cost barrier for their drug discovery programme and allowing rapid sourcing and screening of hit clusters like never before.
- BioAscent collaborated with Heriot-Watt University to identify a molecule that could be used to stop heart stents failing. This project required the use of BioAscent’s Compound Cloud library and its unique robotic capabilities to perform a smart screen of a subset of only 5000 chemicals. The chemical structures of promising candidates were then analysed and similar molecules cherry-picked from the full library to identify I942.
- BioAscent’s Compound Cloud library was used by the ALBORADA Drug Discovery Institute for virtual screening and to progress promising leads against a novel Huntington’s disease target. The ALBORADA team obtained compounds from a variety of sources in order to prosecute a drug discovery program. Approaches employed included fragment screening, diversity screening and virtual screening, which used BioAscent’s on-demand Compound Cloud service. The institute identified small molecule inhibitors of the PI5P4 kinases and have shown in a range of cell types, including primary neurons, that these compounds upregulate autophagy. The most advanced hits in this program were based on the initial Compound Cloud hits.
- Whilst on his PhD placement at BioAscent, George Pandarakalam (now a Senior Scientist in the Biology team), worked on an assay development project at the European Screening Centre, which was titled ‘Spliced Leader Trans-splicing: A Target for the Identification of Novel Anthelmintic Drugs’. At BioAscent, George miniaturised an assay he had developed in the university laboratory into a 384-/1536- well format, carried out automation of some of the steps, and performed the screening of BioAscent’s Compound Cloud.
To read the Journal of Medicinal Chemistry publication in full, click here.
To find out more, and to access the unique, on-demand Compound Cloud service, click here.